HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter

Permalink
https://escholarship.org/uc/item/2gg8m6nt

Journal
Journal of NeuroVirology, 20(3)

ISSN
1355-0284

Authors
Keltner, JR
Fennema-Notestine, C
Vaida, F
et al.

Publication Date
2014

DOI
10.1007/s13365-014-0236-8

Peer reviewed
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter

John R. Keltner · Christine Fennema-Notestine · Florin Vaida · Dongzhe Wang · Donald R. Franklin · Robert H. Dworkin · Chelsea Sanders · J. Allen McCutchan · Sarah L. Archibald · David J. Miller · George Kesidis · Clint Cushman · Sung Min Kim · Ian Abramson · Michael J. Taylor · Rebecca J. Theilmann · Michelle D. Julaton · Randy J. Notestine · Stephanie Corkran · Mariana Cherner · Nichole A. Duarte · Terry Alexander · Jessica Robinson-Papp · Benjamin B. Gelman · David M. Simpson · Ann C. Collier · Christina M. Marra · Susan Morgello · Greg Brown · Igor Grant · J. Hampton Atkinson · Terry L. Jernigan · Ronald J. Ellis · for the CHARTER Group

Abstract Despite modern antiretroviral therapy, HIV-associated sensory neuropathy affects over 50 % of HIV patients. The clinical expression of HIV neuropathy is highly variable: many individuals report few symptoms, but about half report distal neuropathic pain (DNP), making it one of the most prevalent, disabling, and treatment-resistant complications of HIV disease. The presence and intensity of pain is not fully explained by the degree of peripheral nerve damage, making it unclear why some patients do, and others do not, report pain. To better understand central nervous system contributions to HIV DNP, we performed a cross-sectional analysis of structural magnetic resonance imaging volumes in 241 HIV-infected participants from an observational multi-site cohort study at five US sites (CNS HIV

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with the Johns Hopkins University, Mount Sinai School of Medicine, University of California, San Diego, University of Texas, Galveston, University of Washington, Seattle, Washington University, St. Louis and is headquartered at the University of California, San Diego and includes: Director: Igor Grant, M.D.; Co-Directors: J. Allen McCutchan, M.D., Ronald J. Ellis, M.D., Ph.D., Thomas D. Marcotte, Ph.D.; Center Manager: Donald Franklin, Jr.; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), J. Allen McCutchan, M.D., Terry Alexander, R.N.; Laboratory, Pharmacology and Immunology Component: Scott Letendre, M.D. (P.I.), Edmund Capparelli, Pharm.D.; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., Steven Paul Woods, Psy.D., Matthew Dawson; Virology Component: David Smith, M.D. (P.I.); Imaging Component: Christine Fennema-Notestine, Ph.D. (P.I.), Terry L., Jernigan, Ph.D., Michael J. Taylor, Ph.D., Rebecca J. Theilmann, Ph.D., John Hesselink, M.D.; Data Management Unit: Anthony C. Gamst, Ph.D. (P.I.), Clint Cushman; Statistics Unit: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D.; Protocol Coordinating Component: Thomas D. Marcotte, Ph.D. (P.I.); Johns Hopkins University Site: Justin McArthur (P.I.), Mary Smith; Mount Sinai School of Medicine Site: Susan Morgello, M.D. (Co-P.I.) and David Simpson, M.D. (Co-P.I.), Letty Mintz, N.P., Cheuk Tang, Ph.D., and Thomas Naidich, M.D.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.), Will Toporoff, N.P.; University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.) and Christina Marra, M.D. (Co-P.I.), Kenneth Maravilla, MD, KC Stegbauer, Ph.D., Trudy Jones, M.N., A.R.N.P.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.D. (P.I.), Eleanor Head, R.N., B.S.N., Gregory Chaljub, M.D.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., Mengesha Teshome, M.D.

Electronic supplementary material The online version of this article (doi:10.1007/s13365-014-0236-8) contains supplemental material, which is available to authorized users.

J. R. Keltner  (✉) · C. Fennema-Notestine · D. R. Franklin · C. Sanders · S. L. Archibald · C. Cushman · I. Abramson · M. J. Taylor · M. D. Julaton · R. J. Notestine · S. Corkran · M. Cherner · N. A. Duarte · G. Brown · I. Grant · J. H. Atkinson · T. L. Jernigan
Department of Psychiatry, University of California San Diego, 220 Dickinson St., San Diego, CA 92103, USA
e-mail: jkeltner@ucsd.edu

F. Vaida
Department of Family and Preventative Medicine, University of California San Diego, San Diego, CA, USA

D. Wang · D. J. Miller · G. Kesidis
Department of Electrical Engineering, Pennsylvania State University, State College, PA, USA

Published online: 19 February 2014
Anti-Retroviral Treatment Effects Research Study (CHAR
ter). The association between DNP and the structural imaging outcomes was investigated using both linear and nonlinear (Gaussian Kernel support vector) multivariable regression, controlling for key demographic and clinical variables. Severity of DNP symptoms was correlated with smaller total cerebral cortical gray matter volume ($r=-0.24$; $p=0.004$). Understanding the mechanisms for this association between smaller total cortical volumes and DNP may provide insight into HIV DNP chronicity and treatment resistance.

**Keywords** HIV distal neuropathic pain · Structural MRI · Cortical volume

**Introduction**

Persistent pain now affects so many individuals with HIV infection that it has recently been termed an “evolving epidemic” (Wiebe et al. 2011). HIV-associated distal neuropathic pain (DNP) is one of the most prevalent neurologic complications of HIV infection in the era of combination antiretroviral therapy (CART), affecting approximately 20% of patients (Ellis et al. 2010). HIV DNP is typically refractory to current chronic pain therapies (Simpson et al. 2008; Verma et al. 2004) and is associated with unemployment, impairment in activities of daily living, and significantly diminished quality of life (Ellis et al. 2010). Despite the prevalence, persistence, and impact of HIV DNP, little is known of its neurobiological underpinnings.

Over half of HIV-infected patients have sensory neuropathy by physical examination or nerve conduction studies (Ellis et al. 2010; Robinson-Papp et al. 2010). About 40% of them report chronic DNP, while the remainder report only numbness or paresthesiae or no symptoms at all (Ellis et al. 2010; Robinson-Papp et al. 2010). Most research on HIV DNP mechanisms has focused on the direct effects of HIV or antiretroviral drugs on peripheral nerves (e.g., exposure to dideoxynucleoside reverse-transcriptase inhibitors such as stavudine or didanosine) and on clinical risk factors for neuropathy (age, height, and lower CD4 nadir) (Ellis et al. 2010). This research suggests the intensity of DNP is not fully explained by the extent of HIV damage to peripheral nerve fibers (Cherry et al. 2005; Dorsey and Morton 2006; Herrmann et al. 2004; Skopolitis et al. 2007) or by clinical risk factors (Ellis et al. 2008, 2010), leaving it unclear why some neuropathy patients experience DNP and others do not.

Central nervous system pathways may exert a major influence on the clinical expression of peripherally induced pain (Apkarian et al. 2005; Lee and Tracey 2010; Ossipov et al. 2010) and contribute to the transition from acute to chronic pain states (Borsook 2011; Baliki et al. 2012). Chronic pain has been associated with reduced cortical brain volumes (Apkarian et al. 2004; Baliki et al. 2011; May 2008; 2009; 2011; Smallwood et al. 2013). A better understanding of brain structure therefore might help explain the variable DNP presentations for patients with HIV-associated sensory neuropathy. Despite its potential usefulness, no reports of brain imaging to investigate HIV DNP have been published. Application of neuroimaging in this arena may be potentially confounded by neuromedical and neuropsychiatric comorbidities such as HIV itself, traumatic brain injury (Lin et al. 2011), depression (Grieve et al. 2013; Truong et al. 2013), and abuse of drugs, such as alcohol (Geibprasert et al. 2010), inhalants (Borne et al. 2005; Geibprasert et al. 2010), and methamphetamine (Jernigan et al. 2005), which are associated with changes in regional brain volumes. In particular, HIV distal neuropathic pain is associated with depression (Lucey R. H. Dworkin
Department of Anesthesiology, University of Rochester Medical Center, Rochester, NY, USA

J. A. McCutchan
Department of Medicine, University of California San Diego, San Diego, CA, USA

S. M. Kim
Department of Bioengineering, University of California, San Diego, CA, USA

R. J. Theilmann
Department of Radiology, University of California San Diego, San Diego, CA, USA

T. Alexander · R. J. Ellis
Department of Neurosciences, University of California San Diego, San Diego, CA, USA

J. Robinson-Papp · D. M. Simpson · S. Morgello
Department of Neurology, The Mount Sinai School of Medicine, New York, NY, USA

B. B. Gelman
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA

A. C. Collier · C. M. Marra
Department of Medicine, University of Washington, Seattle, WA, USA

J. R. Keltner · G. Brown · J. H. Atkinson
VA San Diego Healthcare System, San Diego, CA, USA
et al. 2011; Keltner et al. 2012) and depression can contribute to changes in brain structure (Grieve et al. 2013; Truong et al. 2013). Thus, neuroimaging research must be conducted within the context of a comprehensive evaluation if results are to be interpretable.

We performed a cross-sectional analysis of regional brain volumes measured by structural magnetic resonance imaging (MRI) in 241 HIV-infected individuals, 66 with DNP, and 175 without DNP, participating in an observational multi-site cohort study. Since total cortical gray matter is reduced in volume in persons with chronic back pain (Apkarian et al. 2004; Balikie et al. 2011), we hypothesized that more severe DNP symptoms would be associated with smaller total cortical gray matter volume. Because participants underwent concurrent standardized medical, neurological, neuropsychological, and psychiatric evaluation, we could statistically control for confounding conditions.

Methods

Participants

Of 1,556 HIV patients at five US academic medical centers participating in the CNS (Central Nervous System) HIV Anti-Retroviral Therapy Effects Research Study (CHARTER), 241 underwent structural MRI (Jernigan et al. 2011). The sites performing MRI included: Johns Hopkins University (Baltimore, MD, n=47); Mount Sinai School of Medicine (New York, NY, n=48); University of California at San Diego (San Diego, CA, n=70); University of Texas Medical Branch (Galveston, TX, n=46); and University of Washington (Seattle, WA, n=30). The 241 participants in the MRI substudy met criteria for and agreed to undergo an MRI (Jernigan et al. 2011). Data reported here are from their first MRI at their second CHARTER visit, which occurred 6 months after the baseline CHARTER visit.

Standard protocol approvals and patient consents

These procedures were approved by the Human Subjects Protection Committees of each participating institution. Written informed consent was obtained from all study participants as part of enrollment into the peripheral neuropathy and MRI substudy.

Measures and assessments

Diagnosis of HIV sensory neuropathy

Using procedures described in detail in a prior publication (Ellis et al. 2010), the diagnosis of HIV Sensory Neuropathy (HIV-SN) was rendered by physicians and nurses trained in neurological AIDS disorders based on a standardized, neurological examination evaluating HIV-associated sensory neuropathy signs, including diminished ability to recognize vibration and reduced sharp-dull discrimination in the feet and toes or reduced ankle reflexes. We defined at least one sign of neuropathy bilaterally as evidence of HIV sensory neuropathy. Of the 241 participants in this substudy, 102 had no signs of neuropathy, 69 had one sign, and 70 had two or more signs. Of the 102 participants with no signs of neuropathy, 9 (9%) had DNP (defined below); of the 69 participants with one sign of neuropathy, 20 (29%) had DNP; and of the 70 participants with two or more signs of neuropathy, 37 (53%) had DNP.

Diagnosis of HIV distal neuropathic pain

As described previously (Ellis et al. 2010; Robinson-Papp et al. 2010), HIV DNP was defined as a specific pattern of bilateral burning, achin, or shooting pain in a distal gradient in the lower extremities. Recognizing that this specific pattern of pain may occur in small fiber-predominant neuropathies in which clinical exam abnormalities are sometimes absent due to the relative paucity of large fiber involvement, we included in the diagnosis of DNP those cases that did not have abnormal clinical exam findings. Indeed, some cases of HIV-SN have been shown to manifest predominantly small fiber involvement. Study clinicians classified DNP into five categories of severity: none, slight (occasional, fleeting), mild (frequent), moderate (frequent, disabling), and severe (constant, daily, disabling, requiring analgesic medication or other treatment). In the statistical model these categories were treated as continuous variables: 0=none (175 participants), 1=slight (18 participants), 2=mild (22 participants), 3=moderate (10 participants), and 4=severe (16 participants). In the assessments of DNP severity, additional characteristics were elicited including the continuity as well as its impact on daily activities and the need for analgesic medications.

Medical evaluation

Clinicians conducting the neurological examination also performed semi-structured interviews and standardized examinations to ascertain HIV disease status, HIV treatment history, psychotropic medications, and pain treatments. Venipuncture and lumbar puncture were performed. Plasma and cerebrospinal fluid (CSF) HIV concentration were determined by reverse transcription polymerase chain reaction ultrasensitive assay (nominal lower quantitation limit, 50 copies/mL [Amplicor; Roche Diagnostic Systems, Indianapolis, Indiana]) and assayed for co-
infection with hepatitis C virus (Hepatitis C Virus Antibody Assay [HCV]; LabCorp, Burlington, North Carolina). Current peripheral blood CD4+ T cell concentration was measured by flow cytometry. We also obtained historical indicators of HIV disease such as the lowest ever CD4 lymphocyte count (CD4 nadir) by chart review or participant recall, since CD4 nadir<200 is associated with worse neuromedical outcomes. Immune recovery was calculated as the difference between the nadir CD4 and current measured CD4 levels.

An extensive treatment history queried for prior and current combination antiretroviral drugs (CART) and patients were categorized as currently using, past history of, or never used CART. We assessed past and current use of a protease inhibitor or a non-nucleoside reverse-transcriptase inhibitor; total number of protease inhibitors being used and for exposure to dideoxynucleoside reverse-transcriptase inhibitors (didanosine, stavudine, and zalcitabine) since these agents cause neuropathy. Finally, we surveyed for current pain treatment with opioids, tricyclic and other antidepressants, and/or anticonvulsants.

Neurocognitive impairment: global deficit score

HIV is associated with brain atrophy and cognitive impairment (Herrmann et al. 2004; Jernigan et al. 2011). Neuropsychological function was assessed with a battery of tests that yields a Global Deficit Score (GDS) ranging from 0=no to 9=severe impairment and calculated from less than expected performance after adjustments for age, education, and ethnicity/race on each test. Global deficit scores are highly effective in identifying neuropsychological impairment in HIV patients when an adequate numbers of tests are used (Carey et al. 2004).

Traumatic brain injury

Since brain trauma can impact regional brain volumes, history of traumatic brain injury (TBI) was obtained using a standardized medical history (Lin et al. 2011). A traumatic brain injury score (ranging from 0 to 4) was determined for each patient based on history obtained from a structured neuromedical and a neuropsychological interview (Lin et al. 2011). Of the 241 participants in this study, 54 provided an inconsistent history in the two interviews, so their traumatic brain injury status was rated as “unknown”. Of the remaining 187, 45 had no history of TBI (TBI score=0); 128 had a history of concussion or head injury with 0–30 min loss of consciousness (TBI score=1); 12 had a history of loss of consciousness greater than 30 min (TBI score=2); 1 had a history of brain trauma complicated by neurological deficits lasting greater than 2 weeks (TBI score=3); and 1 had a history of brain trauma with permanent residual neurological and motor impairments (TBI score=4).

Psychiatric and substance misuse disorders

Because psychiatric and substance use disorders may be associated with neuroimaging and cognitive abnormalities, current (e.g., within the last 30 days) and lifetime history of major depression and psychoactive substance use disorders were assessed by the computer-assisted Composite International Diagnostic Interview (Wittchen et al. 1991). History of abuse and dependence was collected for alcohol, cannabis, cocaine, hallucinogens, inhalants, methamphetamine, opioids, and sedatives.

The Beck Depression Inventory-second edition (BDI-II) (Beck 1996), which has been validated for HIV populations (Lipps et al. 2010), was used to assess depressive symptoms over the past 2 weeks. The BDI-II consists of 21 questions, each having four graded statements (labeled 0 to 3) ordered to show increasing severity of depressive symptoms. Four categories/levels of depression severity are derived based upon the total numerical score: 0–13=Minimal; 14–19=Mild; 20–28=Moderate; 29–63=Severe.

Structural imaging analysis methods

As described previously (Jernigan et al. 2011), structural MRI volumes were acquired on 1.5-T GE scanners at the five participating sites. Four series were acquired for multi-channel tissue segmentation and anatomy: Series 1 and 2 were coronal acquisitions with section thickness=2.0 mm, FOV 24 cm, matrix size 256×256: 2D T2-weighted fast spin echo (FSE) with TR=5,700 ms, TE=90 ms, ETL=16; and 2D proton density (PD) weighted FSE with TR=3,700 ms, TE=17 ms, ETL=4. Series 3 and 4 were sagittal acquisitions with section thickness=1.3 mm, FOV 24 cm, matrix size 256×256×124: 3D T1-weighted SPGR with TR=20 ms, TE=6 ms, flip angle=30; and 3D PD-weighted SPGR sequence with TR=20 ms, TE=6 ms, flip angle=5.

The standard multi-channel morphometric analysis method employed by the CHARTER study (Jernigan et al. 2011) provided measures of cortical and subcortical gray matter; total cerebral white matter and abnormal white matter; and ventricular and sulcal CSF (Fig. 1). This approach includes image inspection for motion and other artifacts; bias correction; coregistration of MRI volumes; re-slicing in a standard space; selection of tissue samples in gray matter, white matter, and CSF by trained neuro-anatomist masked to other patient information; removal of non-brain voxels; automated tissue segmentation; abnormal white matter designation; and anatomical segmentation. Information from all four MRI series
described above is leveraged for the multi-channel approach. Tissue segmentation is based on successive linear regressions on the tissue samples to separate CSF from brain and then to separate gray from white matter. In this approach, abnormal white matter regions are defined as voxels within the total cerebral white matter that have signal values that fall in (or beyond) the distribution estimated from the gray matter sample (i.e., outside the range of normal white matter, for example, hyperintense regions on T2), and these voxels are segmented as “gray”. Anatomists processed the tissue-segmented images manually to separate the cerebellum from the cerebrum, the ventricles from subarachnoid space, and cortical from subcortical gray matter within the cerebrum. Cortical gray matter volumes include neocortex and the hippocampus and amygdala; subcortical gray matter volumes include the caudate, putamen, nucleus accumbens, thalamus, and some substantia nigra and ventral diencephalic regions.

Statistical methods

The association between DNP and the structural imaging variables was investigated using univariable and multivariable regression to predict DNP severity rating (from 0 = none to 4 = severe). DNP was treated as a continuous variable in the statistical analyses. All structural volumes were log transformed to symmetrize the distributions and stabilize the variances. Supratentorial cranial vault volume and scanner were included as covariates in both univariable and multivariable analyses to control for individual differences in head size as well as differences in scanners across sites (Fennema-Notestine et al. 2007; Jernigan et al. 2011).

In the multivariable analyses, the model is subject to a model selection step, whereby only potential confounders that are significant at the 0.20 level are included in the final multivariable model. In addition, in the multivariable analyses we controlled for variables that may impact regional brain volumes based on previous work (Borne et al. 2005; Geibprasert et al. 2010; Jernigan et al. 2005; Jernigan et al. 2011; Grieve et al. 2013; Truong et al. 2013). These included socio-demographic characteristics (age, gender, race/ethnicity, education); clinical characteristics and comorbidities (plasma and cerebrospinal fluid HIV RNA levels—detectable versus undetectable); number of signs of neuropathy (0 signs, 1 sign, 2 or more signs); current and nadir CD4+ T cell counts; hepatitis C serology (positive versus negative); neurocognitive impairment (Global Deficit Score); treatment history (current antiretroviral treatment—yes or no, antiretroviral regimen type, number of protease inhibitors, antiretroviral dideoxynucleoside reverse-transcriptase inhibitors use—current and past use as well as current and past total exposure); history of substance abuse and dependence (yes or no for alcohol, cannabis, cocaine, hallucinogens, inhalants, methamphetamine, opiates, and sedatives); depression characteristics (yes or no for diagnosis of major depression—current and past, as well as total BDI-II score); and current use of analgesic medication (opioids, tricyclic antidepressants/serotonin norepinephrine reuptake inhibitors, anticonvulsants).

In the multivariable models, a subject was excluded if data for that subject was missing from any explanatory variable included in the model. Traumatic brain injury was not included in our multivariable analysis since over 25 % of the subjects were missing TBI scores: 54 subjects had unknown TBI scores due to inconsistent TBI reports; however, we did complete a multivariable analysis investigating the association of DNP with log cortical volumes where TBI was included in the model selection process.

For both the univariable and multivariable analyses, we calculated the proportional difference in mean brain volume per one unit of DNP severity (and 95 % CI) as determined by
exponentiating the regression coefficient of DNP in the log-volume analysis; the Cohen’s d effect size associated with DNP and 95% confidence intervals; the corresponding p value from the t test of regression with Bonferroni correction for multiple comparisons—each p value was multiplied by 6 since six different analyses were performed for each regional brain volume; the total R-squared model fit; and the partial R-squared model fit for DNP. The partial R-squared model fit for DNP between each regional brain volume vs DNP, $R^2_{DNP}$, was calculated using the formula (Cohen et al. 2003), $R^2_{DNP}=(R^2_{DNP, Other}−R^2_{Other})/(1−R^2_{Other})$, where $R^2_{DNP, Other}$ is the R-squared model fit for the multivariable regression between each regional brain volume and confounding variables (significant at the $p=0.20$ level) included in the final multivariable model as well as DNP, while $R^2_{Other}$ is R-squared model fit for the multivariable regression between the regional brain volume and these same confounding variables without DNP. All tests were two-sided, and statistical significance was declared at the 0.05 level. All computations were done using JMP (SAS Institute, Cary, North Carolina, USA) and R statistical platforms (R Foundation, Vienna, Austria).

In follow-up analyses, using logistic regression we investigated how the odds of pain decreased for increasing adjusted log cortical volumes where the adjusted log cortical volumes were divided into quartiles. The adjusted log cortical volumes were the residuals from a linear regression using log cortical volumes as the dependent variable and explanatory variables from the multivariable analyses that were significant at the $p=0.20$ level as the independent variables.

In addition, the correlation was calculated between log cortical volumes versus severity of DNP using a scatterplot of adjusted log cortical volume residuals plotted vs adjusted DNP residuals; the adjusted log cortical volumes and the adjusted DNP were again calculated using explanatory variables from the multivariable log cortical volume model that were significant at the $p=0.20$ level.

### Results

The demographic and clinical characteristics of the study participants (Table 1) show that typical patients were middle-aged men of Caucasian and African American ethnicity who had AIDS and were currently on antiretrovirals, with good immune recovery and fair virologic control.

As a point of reference for conceptualizing the MRI results, Fig. 1 illustrates typical T1 and T2 slices images used in the multi-channel morphometric segmentation of regional brain volumes, as well as ventricular and subarachnoid CSF, abnormal and total white matter, and total cortical and subcortical gray matter.

**Table 1** Demographic and clinical characteristics of participants, both with and without distal neuropathic pain (DNP)

<table>
<thead>
<tr>
<th>Description</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of subjects</td>
<td>241</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>43.8 (7.9)</td>
</tr>
<tr>
<td>Education yrs, mean (SD)</td>
<td>12.8 (2.5)</td>
</tr>
<tr>
<td>Male, no. (%)</td>
<td>192 (80)</td>
</tr>
<tr>
<td>Race/ethnicity, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>93 (39)</td>
</tr>
<tr>
<td>African American</td>
<td>115 (48)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>27 (11)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Hepatitis C virus seropositive, no. (%)</td>
<td>68 (28)</td>
</tr>
<tr>
<td>AIDS, no. (%)</td>
<td>152 (63)</td>
</tr>
<tr>
<td>Global Deficit Score, mean (SD)</td>
<td>0.46 (0.46)</td>
</tr>
<tr>
<td>CD4, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Current&lt;200; Nadir&lt;200</td>
<td>34 (14)</td>
</tr>
<tr>
<td>Current$\geq$200, Nadir&lt;200</td>
<td>106 (44)</td>
</tr>
<tr>
<td>Current$\geq$200, Nadir$\geq$200</td>
<td>98 (41)</td>
</tr>
<tr>
<td>CART use, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>177 (73)</td>
</tr>
<tr>
<td>Past</td>
<td>37 (15)</td>
</tr>
<tr>
<td>Never</td>
<td>27 (11)</td>
</tr>
<tr>
<td>Plasma HIV RNA detectable, no. (%)</td>
<td>122 (51)</td>
</tr>
<tr>
<td>ON CART, no. (%)</td>
<td>61 (35)</td>
</tr>
<tr>
<td>OFF CART, no. (%)</td>
<td>61 (97)</td>
</tr>
<tr>
<td>Cerebrospinal Fluid HIV RNA Detectable, no (%)</td>
<td>69 (32)</td>
</tr>
<tr>
<td>ON CART, no. (%)</td>
<td>24 (16)</td>
</tr>
<tr>
<td>OFF CART, no. (%)</td>
<td>45 (76)</td>
</tr>
<tr>
<td>Current antiretroviral regimen, no. (%)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>64 (26)</td>
</tr>
<tr>
<td>PI-based</td>
<td>96 (54)</td>
</tr>
<tr>
<td>NNRTI-based</td>
<td>61 (34)</td>
</tr>
<tr>
<td>PI+NNRTI-based</td>
<td>10 (6)</td>
</tr>
<tr>
<td>Other</td>
<td>11 (6)</td>
</tr>
<tr>
<td>D-drug use, past or current, no. (%)</td>
<td>132 (55)</td>
</tr>
<tr>
<td>Lifetime Major Depressive Disorder*, no. (%)</td>
<td>52 (22)</td>
</tr>
<tr>
<td>Current Major Depressive Disorder*, no. (%)</td>
<td>27 (11)</td>
</tr>
<tr>
<td>Beck Depression Inventory II, Mean (SD)</td>
<td>12.3 (11.0)</td>
</tr>
<tr>
<td>Neuropathic pain rating, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Slight</td>
<td>18 (7)</td>
</tr>
<tr>
<td>Mild</td>
<td>22 (9)</td>
</tr>
<tr>
<td>Moderate</td>
<td>10 (4)</td>
</tr>
<tr>
<td>Severe</td>
<td>16 (6)</td>
</tr>
<tr>
<td>Zero signs of neuropathy, no (%)</td>
<td>102 (42)</td>
</tr>
<tr>
<td>One sign of neuropathy</td>
<td>69 (29)</td>
</tr>
<tr>
<td>Two signs of neuropathy</td>
<td>70 (29)</td>
</tr>
<tr>
<td>In those with no signs of neuropathy, no (%)</td>
<td></td>
</tr>
<tr>
<td>HIV distal neuropathic pain</td>
<td>9 (9)</td>
</tr>
<tr>
<td>No HIV distal neuropathic pain</td>
<td>93 (91)</td>
</tr>
<tr>
<td>In those with one sign of neuropathy, no (%)</td>
<td></td>
</tr>
<tr>
<td>HIV distal neuropathic pain</td>
<td>20 (29)</td>
</tr>
<tr>
<td>No HIV distal neuropathic pain</td>
<td>49 (71)</td>
</tr>
</tbody>
</table>
Univariable and multivariable analyses of the association of DNP with the structural imaging outcomes (Table 2) reveal that worse (higher) clinician-assessed DNP rating was associated with lower total cortical gray matter volume. In the univariable analyses, worse DNP was associated with larger ventricular CSF volume. In both the univariable and multivariable analyses, the DNP rating was not associated with subcortical gray matter volumes, abnormal white matter volume, white matter total volume, or sulcal CSF volume.

DNP was present, but neuropathy signs absent, in only 9 of 66 subjects with DNP (14%). Excluding these nine cases did not alter the relationship between severity of DNP symptoms and smaller total cerebral cortical gray matter volume ($R^2=0.82; p=0.004$).

Note that TBI was not included in the multivariable model as described in the statistical methods section. When TBI is included as a variable in the model selection step for the multivariable analysis investigating the association of DNP with the log cortical volumes, the calculated variables in Table 2 are not significantly different for all variables: percent change in proportional difference in mean brain volume per one unit of DNP, effect size, $p$ value, the $R^2$ model fit, and the partial $R^2$ model fit for DNP.

The odds of pain decreased by a factor of $OR=1.42$, 95% CI=$(1.08, 1.87)$ for each increasing quartile of adjusted log cortical brain size. The proportions of frequency of distal neuropathic pain for each quartile of adjusted log cortical volume are plotted in Fig. 2.

We calculated the linear correlation coefficient between adjusted log cortical volume residuals plotted vs adjusted DNP residuals ($r=-0.24 p=0.0003$), see Fig. 3. The $R^2$ squared fit=0.059 for this linear fit agrees with the
Given previous investigation of the impact of HIV on brain structure (Jernigan et al. 2011), it is notable that DNP severity was correlated with age ($r=0.22$, $p=0.006$) but was not significantly correlated with CD4 nadir, dideoxynucleoside reverse-transcriptase inhibitors use (current or past), or global deficit score.

The explanatory variables used for each multivariable linear regression model of the association between DNP and log brain volumes are shown in supplementary Table, S1. In this table, the definition (type and range), number of subjects with missing data for each variable, and the $p$ values (uncorrected for multiple comparisons) less than 0.20 (based on linear regression) are listed for each explanatory variable in this table. Supplementary Table S2 gives variable ranking results based on nonlinear regression.

**Discussion**

Consistent with our hypothesis and with previously reported findings in HIV-uninfected persons, more severe DNP was associated with smaller volumes of total cerebral cortical gray matter in HIV-infected patients. To better understand associations between HIV pain and brain volume, we statistically controlled for several HIV disease-related factors and non-HIV characteristics (e.g., substance abuse and depression) that could contribute to this relationship.

A distal, sensory predominant, axonal neuropathy can be demonstrated by clinical examination, by nerve conduction studies, by quantitative sensory testing, and skin biopsy analysis of epidermal nerve fiber density in more than half of HIV-infected individuals on long-term antiretroviral therapy (Robinson-Papp et al. 2010; Simpson et al. 2006). Chronic DNP and disability are reported by some patients, yet many remain asymptomatic or experience only non-painful symptoms such as paresthesiae and numbness. This raises the question of why the clinical phenotype (DNP) varies between individuals who have similar underlying signs of peripheral neuropathy. Differences in central nervous system pain processing are one possible explanation for the variation in expression of DNP for HIV patients.

Possible explanations for the observed correlations between increased DNP severity and smaller total cortical gray matter volumes include: (1) DNP causes reduced cortical volumes, (2) reduced cortical volumes cause DNP, (3) both reduced cortical volumes and DNP are causally linked to a third, confounding variable, and (4) statistical coincidence. Alternatively, cortical atrophy may be a surrogate marker—rather than a direct cause itself—for a pathological process that directly alters pain perception. For example, cortical volume loss may track with neuronal damage in circuits responsible for the central processing of emotional and cognitive information about pain.

The repeated observation that successful treatment of chronic pain can normalize regional brain volumes suggests that the direction of causality may be from chronic pain to
reductions in regional brain volumes (Gwilym et al. 2010; Rodriguez-Raecke et al. 2009; Seminowicz et al. 2011; May 2011). Moreover, multiple chronic pain syndromes such as headache (Schmitz et al. 2008) and back pain (Apkarian et al. 2004; Baliki et al. 2011), are associated with smaller regional cerebral cortical gray volumes (May 2011; Smallwood et al. 2013). Our result that total cortical gray matter is smaller for patients with HIV DNP is consistent with Apkarian and Baliki et al. 2011; Smallwood et al. 2013). Our result that total cortical gray matter is smaller in patients with chronic back pain (Apkarian et al. 2004; Baliki et al. 2011). Interestingly, total cortical gray matter volume is not reduced in patients with complex regional pain syndrome and knee osteoarthritis (Baliki et al. 2011). It has been suggested that different chronic pain syndromes exhibit unique structural brain imaging anatomical “brain signatures” (Baliki et al. 2011).

The effects of DNP appear to be regionally different and unrelated to biomarkers of HIV infection. HIV is associated with decreased basal ganglia volume, increased abnormal white matter volume, and, to a lesser extent, decreased cortical volumes; so HIV may have contributed to brain atrophy in our sample (Jernigan et al. 2011; Paul et al. 2002). However, HIV most often is associated with alterations of subcortical gray and white matter and DNP was not associated with these regional volumes. Moreover, effects of DNP were independent of HIV-related factors such as viral load and CD4+ T cell count that were accounted for in the multivariable model.

On the other hand, cortical atrophy may contribute to the development of chronic pain. For example, the prevalence of chronic pain is increased in several CNS diseases that cause cortical atrophy (Borsook 2011): including Parkinson’s disease (40–60 %), Alzheimer disease (57 %), multiple sclerosis (50–86 %), and traumatic brain injury (57 %). In addition, chronic pain is associated with changes in CNS function, structure, and chemistry, which are thought to contribute to the centralization of chronic pain (Borsook 2011).

This study has several strengths and limitations. It is based in a large prospective, diverse cohort drawn from multiple US sites and provided rigorous standardized assessment of both brain structure and neuromedical variables. Limitations include its cross-sectional design, which leaves us unable to explore possible cause and effect relationships between cortical volumes and HIV DNP. We examined global brain volumes available from the CHARTER study, but have not explored associations of cortical regions with DNP. Our cohort was a convenience sample of patients enrolled in HIV care at academic clinics, rather than from a random sample of the HIV patients in care.

Given the high prevalence and disability caused by HIV-associated DNP, the need to improve understanding of the effects and mechanisms of DNP, and the need to identify therapeutic targets, additional research is warranted to assess whether any regional specificity within the cortex is associated with HIV DNP.

Acknowledgement This research was supported by awards N01 MH22005, R25-MH081482, HHSN271201000027C, R01 MH079752 and P30 MH0625 from the National Institutes of Health. Disclaimer: The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Government. The authors have no conflicts of interest to disclose. Each author John R. Keltner, Christine Fennema-Notestine, Florin Vaida, Dongzhe Wang, Donald R. Franklin, Robert H. Dworkin, Chelsea Sanders, J. Allen McCutchan, Sarah L. Archibald, David J. Miller, George Kesidis, Clint Cushman, Sung Min Kim, Ian Abramson, Michael J. Taylor, Rebecca J. Theilmann, Michelle D. Julaton, Randy J. Notestine, Stephanie Corkran, Mariana Chermer, Nichole A. Duarte, Terry Alexander, Jessica Robinson-Papp, Benjamin B. Gelman, David M. Simpson, Ann C. Collier, Christina M. Marra, Susan Morgello, Greg Brown, Igor Grant, J. Hampton Atkinson, Terry L. Jernigan and Ronald J. Ellis does not have a financial relationship with the National Institutes of Health.

References


